Endoscopy, the standard for detecting esophageal precancer, is quite an invasive procedure — so a lot of people who should be ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...

The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or ...

Among four approaches, perioperative chemotherapy and trimodality therapy were associated with better survival outcomes in ...

BeiGene ($BGNE) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high ...

Across the world, people love drinking endless cups of tea and coffee – that of piping. And now that cold weather is here, ...

11月8日，由河南省肿瘤医院罗素霞教授研究团队开展的一项关于晚期食管鳞状细胞癌（以下简称“ESCC”）治疗，在《Signal Transduction and Targeted Therapy》期刊上发表研究论文《First-line ...

Shares of BeiGene rose Wednesday morning after the company said it has received regulatory approval for its treatment of gastric and esophageal cancers from the European Union. Shares were recently up ...

Achalasia is primarily caused by the degeneration of the myenteric plexus in the esophageal wall, leading to impaired ...

Combination of radiation, chemotherapy and immunotherapy can shrink tumors and allow surgery, with much better survival rate.

The combination of radiation, chemotherapy, and immunotherapy can reduce tumor size and lead to significantly better survival ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, ...